Lixte Biotechnology Q3 2024 Earnings Results & Report

Lixte Biotechnology EPS Results

• Actual EPS: -$0.44
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Lixte Biotechnology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lixte Biotechnology (NASDAQ:NMAD) is a clinical-stage biotechnology company focused on developing novel cancer therapies. The company’s research centers on protein phosphatase 2A (PP2A), an enzyme involved in regulating cell growth, survival and response to treatment. Lixte is developing compounds intended to inhibit PP2A and potentially enhance the effectiveness of existing cancer therapies.

Lixte’s lead investigational product is LB-100, a small-molecule PP2A inhibitor being evaluated for potential use in combination with chemotherapy, radiation and other anticancer treatments. The company’s development programs are focused primarily on oncology indications, although product candidates remain investigational and are subject to clinical and regulatory review.

Lixte Biotechnology Holdings is headquartered in the United States and has historically operated as a research and development company, collaborating with academic and clinical researchers to advance its drug candidates. The company is publicly traded under the symbol LIXT; the symbol NMAD provided in the request does not appear to correspond to Lixte Biotechnology.